Is you current interferon beta treatment any benefit against #MSCOVID19

I

Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta.Brzoska J, von Eick H, Hündgen M.Drug Res (Stuttg). 2020 May 22. doi: 10.1055/a-1170-4395. Online ahead of print.PMID: 32443163

There is a question about whether interferon B can be used for the treatment of COVID-19. This is because interferons are anti-viral. However it is argued here that the dosing used in MS may not be high enough and that the high doses they suggest may cause side effects. They suggest trials but as the first wave is diminishing beta interferon and the occurrence of COVID19 in Germany is low you have to say good luck recruiting to the trials. It will be interesting to see what gets reported to see what interferon beta really did. They are also talking about treatment for severe COVID19. People with MS would be getting the benefit of prophylactic treatement. However, do people taking beta interferfon get COVID-19. The answer is yes. Do they recover? On the whole the answer is yes too, but that is the case for every oe else on MS DMT unless you have the features associated with risk in the general population.

COI multiple

About the author

MouseDoctor

5 comments

  • A small bio pharmaceutical company in California has produced a position paper to justify use of Lambda interferon to ameliorate Covid. Non-clinical studies have shown potent antiviral effects of Lambda interferon against influenza and SARS coronavirus, rotavirus, norovirus, and reovirus. In a human clinical study, Alfa interferon, which boosts the immune system using the same Jak-STAT pathway as Lambda interferon, has already demonstrated antiviral activity against SARS, another coronavirus, resulting in more rapid resolution of lung abnormalities, with a well-established safety profile, having been previously studied in Phase 1, 2 and 3 clinical trials in over 3,000 healthy volunteers and patients. Lambda’s well-established safety profile and its convenient once weekly dosing, supports the drug as a potentially attractive viable antiviral treatment option for COVID-19. We’ll see…

    • This is nothing new I’m afraid I learned about type III interferons weeks ago

      COVID-19 and emerging viral infections: The case for interferon lambda.
      Prokunina-Olsson L, Alphonse N, Dickenson RE, Durbin JE, Glenn JS, Hartmann R, Kotenko SV, Lazear HM, O’Brien TR, Odendall C, Onabajo OO, Piontkivska H, Santer DM, Reich NC, Wack A, Zanoni I.
      J Exp Med. 2020 May 4;217(5):e20200653. doi: 10.1084/jem.20200653.

      • I see…in Italy the way is hard to be tested because of concomitant competitive trials in same population of mild Covid

        • Thanks for your insight. I am sure in the UK there is a problem too the number of people with the condition is rapidly diminishing, will they make the target numbers. In the UK we have the RECOVERY trial, it seems to change every week

          Lopinavir-Ritonavir
          Low-dose Dexamethasone
          Hydroxychloroquine
          Azithromycin
          Tocilizumab
          Convalescent plasma

          You just have to look to the literature to get a feel of which arm was doomed before it started.

          • I have some colleagues in UK in the primary care whose mentioned the PRINCIPLE trial. In Italy the story for GP careers has been the same ( “homemade” protocols with hydroxychloroquine, steroid, antibiotics, anti viral drugs etc..,) to avoid hospitalization 😌😑
            Good night and lots of compliments for your irrepressible work!

By MouseDoctor

Translate

Categories

Recent Posts

Recent Comments

Archives